Shalby surges as its step down arm receives USFDA’s approval for Duraniom
Shalby is currently trading at Rs. 228.80, up by 6.00 points or 2.69% from its previous closing of Rs. 222.80 on the BSE.
The scrip opened at Rs. 228.00 and has touched a high and low of Rs. 231.85 and Rs. 226.90 respectively. So far 5339 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 333.85 on 24-Jan-2024 and a 52 week low of Rs. 204.50 on 21-Nov-2024.
Last one week high and low of the scrip stood at Rs. 233.20 and Rs. 211.00 respectively. The current market cap of the company is Rs. 2483.68 crore.
The promoters holding in the company stood at 74.27%, while Institutions and Non-Institutions held 4.79% and 20.94% respectively.
Shalby’s step down subsidiary -- Shalby Advanced Technologies (SAT) Inc., USA, has received U.S. Food and Drug Administration (USFDA) 510(k) Premarket Notification Clearance for Duraniom, its Primary Total Knee Replacement device with TiNbN coating, on January 14, 2025. Based on the safety and effectiveness data, USFDA has determined the device is substantially equivalent to legally marketed predicate devices.
Shalby is one of the leading multi-specialty chains of hospitals in India.
